Mode
Text Size
Log in / Sign up
N/A N=21 Randomized Single-blind Treatment

Managing Pain and Cognitions in Older Adults With Mild Cognitive Impairment or Memory Related Problems and Chronic Pain

Chronic Pain · Mild Cognitive Impairment · Older Adults · Physical Activity

Enrolled (actual)
21
Serious AEs
Results posted
Jul 2023
Primary outcome: Primary: Client Satisfaction Questionnaire 3-Item (CSQ-3): Number of Participants With Scores Above and Below Scale Midpoint — 8; 9; 0; 1 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Active Brains 1 (Behavioral); Active Brains 2 (Behavioral)
Age
Adult, Older Adult · 60+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Dec 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Client Satisfaction Questionnaire 3-Item (CSQ-3): Number of Participants With Scores Above and Below Scale Midpoint
8; 9; 0; 1; 1; 1
SECONDARY
Proportion of Participants With Valid Digital Monitoring Device Wear
8; 0; 1; 11
SECONDARY
Proportion of Participants With Valid Adherence to Homework
8; 0; 1; 11
SECONDARY
Rate of Interventionist's Delivering the Programs by Following the Established Session Topics and Skills
97.3; 91.4
SECONDARY
Percentage of Missing or Low Reliability Measures (Feasibility of Quantitative Measures)
85; 99
SECONDARY
Proportion of Participants Using Rescue (Non-Narcotic) Analgesics
4; 5
SECONDARY
Proportion of Participants Using Narcotic Analgesics
2; 4
SECONDARY
Credibility and Expectancy Questionnaire (CEQ): Number of Participants With Scores Above and Below Scale Midpoint
9; 11; 0; 0; 5; 4
SECONDARY
Montreal Cognitive Assessment (MoCA)
24.8; 26.3; 26.2; 26.6
SECONDARY
Godin Leisure-Time Exercise Questionnaire
36; 20; 74; 30.8
SECONDARY
Measure of Current Status (MOCS-A)
30.4; 25.6; 36.1; 28.3
SECONDARY
The Measurement of Everyday Cognition (eCog)
2.3; 1.9; 2; 1.8
SECONDARY
Numerical Rating Scale
5.9; 4.4; 3.9; 4.3; 6.2; 5.7
SECONDARY
The Cognitive and Affective Mindfulness Scale - Revised (CAMS-R)
31.9; 33.8; 33.9; 35.3
SECONDARY
WHO Disability Assessment Schedule 2.0
17.1; 23.9; 16; 22.2
SECONDARY
The Gratitude Questionnaire (GQ-6)
36.2; 32.5; 35.5; 35.9
SECONDARY
PROMIS Physical Function
39.9; 37.1; 43.4; 38.2
SECONDARY
PROMIS Emotional Support
51.1; 49.4; 52.1; 48.8
SECONDARY
T-Score for PROMIS Depression
51.6; 55.6; 52.5; 54.3
SECONDARY
T-Score for PROMIS Anxiety
51; 52.9; 47.9; 53.7
SECONDARY
Pain Catastrophizing Scale (PCS)
9.4; 11.6; 7.1; 11
SECONDARY
UCLA Loneliness Scale
12.9; 13.4; 12.6; 13.3
SECONDARY
Pain Self Efficacy Questionnaire (PSEQ)
38; 35.5; 42.9; 38
SECONDARY
Tampa Kinesiophobia Scale
31.9; 37.6; 31.2; 35.8
SECONDARY
Chronic Pain Acceptance Questionnaire
30.1; 24.3; 31; 27.1
SECONDARY
Self-Compassion Scale (SCS)
45.6; 44.4; 43.2; 43.6
SECONDARY
ActiGraph Average Steps
3643.1; 3195.3; 4283.8; 2604.4
SECONDARY
Six-Minute Walk Test (6MWT)
407.6; 415.6; 426.6; 435.2

Summary

We aim to conduct a pilot randomized controlled trial comparing 2 symptom management programs for older adults with self-reported memory problems and chronic pain, Active Brains 1 and Active Brains 2. We will assess how each program may help in improving coping with pain and coping with cognitive functioning. We will explore feasibility, acceptability, and credibility and within group changes in physical, emotional and cognitive functioning.

Eligibility Criteria

Inclusion Criteria

  • Male and female patients, age 60 years or older
  • Have nonmalignant chronic pain for more than 3 months
  • Has MCI or subjective memory related problems
  • Able to perform a 6-minute walk test at an accelerated pace
  • Owns a smartphone with Bluetooth 4.0
  • Willingness and ability to participate in the Active Brains intervention and to comply with the requirements of the study protocol (including weekly sessions and Fitbit use)
  • Free of concurrent psychotropic or pain medication for at least 2 weeks prior to initiation of treatment, OR stable on current psychotropic or pain medication for a minimum of 6 weeks and willing to maintain a stable dose
  • Cleared by a medical doctor for study participation
  • Leads a sedentary lifestyle

Exclusion Criteria

  • Diagnosed with medical illness expected to worsen in the next 6 months
  • Serious mental illness or instability for which hospitalization may be likely in the next 6 months
  • Current suicidal ideation reported on self-report
  • Lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder, or substance dependence
  • Current substance use disorder, within the past 6 months
  • Practice of yoga/meditation, or other mind-body techniques that elicit the relaxation response, once per week for 45 minutes or more within the last 3 months or less
  • Regular use of Fitbit in the last 3 months
  • Engagement in regular intensive physical exercise for >30 minute daily
  • Unable to walk without use of assistance (e.g., wheelchair, walker)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04044183). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search